<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573206</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-0543</org_study_id>
    <nct_id>NCT03573206</nct_id>
  </id_info>
  <brief_title>AMBULATE Continued Access Protocol to Evaluate the Cardiva Mid-Bore Venous Vascular Closure System (VVCS)</brief_title>
  <official_title>Multi-center, Single Arm Continued Access Protocol to Evaluate the Mid-Bore Venous VCS for the Management of the Femoral Venotomy After Catheter-based Interventions Via 6-12F Procedural Sheaths With Single or Multiple Access Sites Per Limb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiva Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiva Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to demonstrate the safety and effectiveness of the Cardiva
      Mid-Bore Venous Vascular Closure System (VVCS) in sealing femoral venous access sites at the
      completion of catheter-based procedures performed through 6-12 Fr introducer sheath, while
      allowing for one or more of the following: elimination of the Foley catheter, elimination of
      protamine, or allowing same (calendar) day discharge for the appropriate patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective multi-center, single arm continued access clinical protocol enrolling subjects
      with multiple femoral venous access sites. All femoral venous access sites will be closed
      using the Cardiva Mid-Bore VVCS. Subjects will be prospectively evaluated for eligibility in
      the three study groups in order to answer specific research questions related to safety and
      effectiveness of the device as it relates to the use of peri-procedural urinary catheters,
      protamine for reversal of heparin, and same calendar day discharge in a select group of
      procedure types.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects will receive the study device for femoral venotomy closure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Procedure Success - Effectiveness</measure>
    <time_frame>30 (+/- 10) days post-procedure</time_frame>
    <description>Final hemostasis at all venous access sites and freedom from major venous access site closure-related complications through 30 days follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Venous Access Site Closure-related Complications - Safety</measure>
    <time_frame>30 (+/- 10) days post-procedure</time_frame>
    <description>Rate of combined majors venous access site closure-related complications attributed directly to the closure method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Group Success Rate - No Urinary Catheter Group</measure>
    <time_frame>From start of procedure through successful ambulation, assessed to be within 6 hours of final hemostasis</time_frame>
    <description>No peri-procedural urinary catheter insertion required through successful Ambulation (per-patient analyses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Group Success Rate - No Protamine Group</measure>
    <time_frame>From time of final hemostasis through successful ambulation, assessed to be within 6 hours of final hemostasis</time_frame>
    <description>No delay in Ambulation due to access site bleeding in subjects who receive heparin but are not reversed with protamine (per-patient analyses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Group Success Rate - Same Calendar Day Discharge Group</measure>
    <time_frame>Within 72 hours post-discharge</time_frame>
    <description>Discharge within the same calendar day from the start of the procedure without the need for re-hospitalization within 72 hours of hospital discharge due to access site complications (per-patient analyses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Evaluated for each access site immediately after device delivery is attempted, reported within 5 minutes of deployment</time_frame>
    <description>The ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with the Mid-Bore VVCS (per-access site analyses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Venous Access Site Closure-related Complications</measure>
    <time_frame>30 (+/- 10) days post-procedure</time_frame>
    <description>Rate of combined majors venous access site closure-related complications attributed directly to the closure method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Surgical Wound</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)</intervention_name>
    <description>The device will be used to close all femoral venous access sites at the end of the case.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pre-Operative Inclusion Criteria:

          -  Acceptable candidate for an elective, non-emergent catheter-based procedure via the
             common femoral vein(s) using a 6 to 12 Fr inner diameter introducer sheath

          -  Must be eligible for at least one of the study groups:

               1. No Urinary Catheter: Candidate to undergo the procedure and bedrest without a
                  urinary catheter

               2. No Protamine: Candidate to receive procedural heparin for anti-coagulation
                  management.

               3. Same Calendar Day Discharge: Expected to undergo a procedure for Supraventricular
                  Tachycardia, Atrial Flutter, Atrial Fibrillation or Ventricular Tachycardia; if
                  heparin is planned, it must be reversed with protamine; and physician is expected
                  to be on site for discharge evaluation

        Pre-Operative Exclusion Criteria:

        Subjects will be excluded from participating in this study if they meet any of the
        following criteria prior to initiation of the index procedure:

          1. Advanced refusal of blood transfusion, if it should become necessary;

          2. Active systemic infection, or cutaneous infection or inflammation in the vicinity of
             the groin;

          3. Pre-existing immunodeficiency disorder and/or chronic use of high dose systemic
             steroids;

          4. Known history of bleeding diathesis, coagulopathy, hypercoagulability, or current
             platelet count &lt; 100,000 cells/mm3;

          5. Severe co-existing morbidities, with a life expectancy of less than 12 months;

          6. Currently involved in any other investigational clinical trial that may interfere with
             the outcomes of this study in the opinion of investigator;

          7. Femoral arteriotomy in either limb with any of the following conditions:

               1. access within &lt; 10 days

               2. any residual hematoma, significant bruising, or known associated vascular
                  complications

               3. use of a vascular closure device within the previous 30 days;

          8. Femoral venotomy in either limb with any of the following conditions:

               1. access within &lt; 10 days

               2. any residual hematoma, significant bruising, or known associated vascular
                  complications c use of a vascular closure device

          9. Any planned procedure involving femoral arterial or venous access in either limb
             within the next 30 days;

         10. Any history of deep vein thrombosis, pulmonary embolism or thrombophlebitis;

         11. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than
             30%;

         12. Females who are pregnant, planning to become pregnant within 3 months of the
             procedure, or who are lactating;

         13. Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20
             kg/m2);

         14. Unable to routinely walk at least 20 feet without assistance;

         15. Known allergy/adverse reaction to bovine derivatives;

         16. Administration of low molecular weight heparin (LMWH) within 8 hours before or after
             the procedure;

         17. Planned procedures or concomitant condition(s) that may extend ambulation attempts
             beyond 2-3 hours, and/or hospitalization time (e.g., staged procedure, serious
             co-morbidity), in the opinion of the Investigator.

        Intra-Operative Inclusion Criteria:

        The subject must be eligible for at least one of the following study groups:

          1. Same Calendar Day Discharge (all criteria apply):

               -  In the Investigator's opinion, the subject is a candidate for Same Calendar Day
                  Discharge per protocol.

               -  If procedural heparin is used, it must be reversed at or before venous closure.

               -  Physician must be on site for discharge evaluation.

               -  Supraventricular Tachycardia (SVT) or Atrial Flutter Subjects: No Additional
                  Criteria

               -  Atrial Fibrillation or Ventricular Tachycardia Procedure Subjects: CHADS2 Score
                  is ≤1, as assessed pre-operatively.

                    -  The subject is not enrolled in the No Protamine Group.

          2. No Urinary Catheter:

             • The subject does not have a urinary catheter inserted/indwelling at the end of the
             procedure, just prior to enrollment.

          3. No Protamine:

               -  The subject received procedural heparin for anti-coagulation management and did
                  not/will not receive protamine.

               -  The subject is not enrolled in the Same Calendar Day Discharge Group

        Intra-Operative Exclusion Criteria:

        Subjects will be excluded from participating in this study if any of the following
        exclusion criteria occur during the index procedure:

          1. Any attempt at femoral arterial access during the procedure;

          2. Any procedural complications that may extend routine recovery, ambulation and
             discharge times;

          3. If the physician deems that a different method should be used to achieve hemostasis of
             the venous access sites, or that the subject should not attempt ambulation according
             to the protocol requirements;

          4. All venous access sites may must comply with the following exclusion criteria,
             assessed immediately prior to enrollment:

               1. Difficult insertion of procedural sheath or needle stick problems at the onset of
                  the procedure (e.g., multiple stick attempts, accidental arterial stick with
                  hematoma, &quot;back wall stick&quot;, etc.) in any of the study veins;

               2. A procedural sheath &lt; 6 Fr or &gt; 12 Fr in inner diameter is present at time of
                  closure;

               3. A procedural sheath &gt; 12 Fr inner diameter at any time during the procedure.

               4. Venous access site location is noted to be &quot;high&quot;, above the inguinal ligament
                  (cephalad to lower half of the femoral head or the inferior epigastric vein
                  origin from the external iliac vein);

               5. Intra-procedural bleeding around sheath, or suspected intraluminal thrombus,
                  hematoma, pseudoaneurysm, or AV fistula;

               6. Length of the tissue tract, the distance between the anterior venous wall and
                  skin, is estimated to be less than 2.5 cm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin M Al-Ahmad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <results_first_submitted>January 6, 2020</results_first_submitted>
  <results_first_submitted_qc>January 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vessel closure</keyword>
  <keyword>venous access site</keyword>
  <keyword>femoral venotomy</keyword>
  <keyword>medium bore</keyword>
  <keyword>multiple access sites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03573206/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (Body Mass Index)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Procedure Success - Effectiveness</title>
        <description>Final hemostasis at all venous access sites and freedom from major venous access site closure-related complications through 30 days follow-up</description>
        <time_frame>30 (+/- 10) days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Procedure Success - Effectiveness</title>
          <description>Final hemostasis at all venous access sites and freedom from major venous access site closure-related complications through 30 days follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Venous Access Site Closure-related Complications - Safety</title>
        <description>Rate of combined majors venous access site closure-related complications attributed directly to the closure method.</description>
        <time_frame>30 (+/- 10) days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Venous Access Site Closure-related Complications - Safety</title>
          <description>Rate of combined majors venous access site closure-related complications attributed directly to the closure method.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Group Success Rate - No Urinary Catheter Group</title>
        <description>No peri-procedural urinary catheter insertion required through successful Ambulation (per-patient analyses)</description>
        <time_frame>From start of procedure through successful ambulation, assessed to be within 6 hours of final hemostasis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Group Success Rate - No Urinary Catheter Group</title>
          <description>No peri-procedural urinary catheter insertion required through successful Ambulation (per-patient analyses)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Group Success Rate - No Protamine Group</title>
        <description>No delay in Ambulation due to access site bleeding in subjects who receive heparin but are not reversed with protamine (per-patient analyses)</description>
        <time_frame>From time of final hemostasis through successful ambulation, assessed to be within 6 hours of final hemostasis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Group Success Rate - No Protamine Group</title>
          <description>No delay in Ambulation due to access site bleeding in subjects who receive heparin but are not reversed with protamine (per-patient analyses)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Group Success Rate - Same Calendar Day Discharge Group</title>
        <description>Discharge within the same calendar day from the start of the procedure without the need for re-hospitalization within 72 hours of hospital discharge due to access site complications (per-patient analyses)</description>
        <time_frame>Within 72 hours post-discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Group Success Rate - Same Calendar Day Discharge Group</title>
          <description>Discharge within the same calendar day from the start of the procedure without the need for re-hospitalization within 72 hours of hospital discharge due to access site complications (per-patient analyses)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>The ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with the Mid-Bore VVCS (per-access site analyses)</description>
        <time_frame>Evaluated for each access site immediately after device delivery is attempted, reported within 5 minutes of deployment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>The ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with the Mid-Bore VVCS (per-access site analyses)</description>
          <units>devices</units>
          <param>Count of Units</param>
          <units_analyzed>devices</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minor Venous Access Site Closure-related Complications</title>
        <description>Rate of combined majors venous access site closure-related complications attributed directly to the closure method.</description>
        <time_frame>30 (+/- 10) days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
          </group>
        </group_list>
        <measure>
          <title>Minor Venous Access Site Closure-related Complications</title>
          <description>Rate of combined majors venous access site closure-related complications attributed directly to the closure method.</description>
          <units>limbs</units>
          <param>Count of Units</param>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days (± 7 days)</time_frame>
      <desc>Access-site related adverse events included</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS): The device will be used to close all femoral venous access sites at the end of the case.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Access site closure-related adverse events, excluding major and minor complications</sub_title>
                <description>Access site venous re-bleeding after initial hemostasis confirmed for 5 minutes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Minor Venous Access Site Closure-Related Complications</sub_title>
                <description>Access site-related hematoma &gt; 6 cm documented by ultrasound</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Minor Venous Access Site Closure-Related Complications</sub_title>
                <description>Pseudoaneurysm requiring thrombin/fibrin adhesive injection or ultrasound-guided compression</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Access site venous re-bleeding after initial hemostasis confirmed for 5 minutes</sub_title>
                <description>Access site venous re-bleeding after initial hemostasis confirmed for 5 minutes</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Access site hematoma ≤ 6 cm</sub_title>
                <description>Access site hematoma ≤ 6 cm</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Access site-related tissue tract oozing – prolonged*</sub_title>
                <description>Access site-related tissue tract oozing – prolonged*</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Bruising at the access site*</sub_title>
                <description>Bruising at the access site*</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pain at the access site</sub_title>
                <description>Pain at the access site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Terry Alverson, Director of Regulatory and Clinical</name_or_title>
      <organization>Cardiva Medical</organization>
      <phone>650-207-0563</phone>
      <email>Terry_Alverson@cardivamedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

